ZHONGCHAO Inc is an offshore holding company... Show more
Zhongchao Inc. is a China-based provider of healthcare information, education, and training services operating under the MDMOOC brand. Founded in 2012 and headquartered in Shanghai, the company delivers online and on-site medical education, patient-management services focused on oncology and rare diseases, and internet healthcare offerings to pharmaceutical enterprises, hospitals, medical associations, and healthcare professionals.
The business historically operated through two segments — MDMOOC services and Sales of Patented Drugs — though the company discontinued its drug-sales segment effective June 30, 2025, to concentrate on its core education and patient-management platform. As a micro-cap issuer with roughly 33 employees and a market capitalization of only a few million dollars, ZCMD attracts attention primarily from investors seeking speculative exposure to China's healthcare technology space. Its profile carries notable structural risks, including a variable interest entity (VIE) arrangement, heavy customer concentration, and a history of Nasdaq listing-compliance challenges.
Over the last 30 days, ZCMD shares fell from roughly $1.38 to near $0.90, a decline of approximately 34%. The slide accelerated in late October and early November as the stock broke decisively below the $1.00 level, marking a fresh leg lower in an already weak tape.
The longer-term trend has been even more pronounced. Over the last quarter, ZCMD has extended a sustained downtrend, falling from a late-September peak near $2.06 to around $0.90 — a drop of roughly 56%. The pattern reflects repeated rallies that have failed to hold, followed by progressively lower lows, consistent with a stock under persistent selling pressure.
The most consequential development in the recent 30-day window was ZCMD's slide back below the $1.00 Nasdaq minimum bid price threshold. After spending much of September and early October trading above that level, the stock broke down through $1.00 in late October, re-exposing the company to renewed delisting and compliance risk.
The decline also reflects the broader reality that a reverse split alone rarely sustains higher prices when underlying fundamentals remain weak. ZCMD's 1-for-8 consolidation in March 2026 temporarily lifted the share price, but with revenue contracting and losses widening, the gains proved short-lived. Thin daily volume and a small public float have compounded the move, allowing relatively modest selling to produce outsized percentage swings in a low-liquidity micro-cap.
The quarterly decline is rooted in a combination of deteriorating financials and persistent structural concerns. Fiscal 2025 results showed revenue falling 28.3% to $11.37 million, a net loss of $5.81 million, and a sharp rise in general and administrative expenses driven by share-based compensation and credit-loss provisions on aged receivables. The discontinuation of the drug-sales segment also removed a revenue source while the company reorients around its core platform.
Beyond the numbers, investors have been weighing recurring risk factors: heavy reliance on a small number of customers (four clients accounted for roughly 61% of revenue), material weaknesses in internal controls, and uncertainty tied to the VIE structure and China's regulatory environment for overseas-listed companies. These issues, combined with the post-reverse-split drift and renewed sub-$1.00 trading, have kept the stock in a prolonged downtrend.
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots drawn from a broader universe of hundreds of automated strategies that trade across thousands of tickers. Rather than listing every available bot, the section highlights top-performing and most relevant strategies, giving traders a focused view of the approaches currently gaining traction in the market. These bots vary widely in strategy, trading timeframe, and performance metrics, so investors can compare different styles before exploring further. For those looking to complement their own analysis of tickers like ZCMD with systematic, data-driven signals, the page offers a useful starting point.
Looking ahead, the most important factor for ZCMD is Nasdaq minimum bid price compliance. Sustained trading below $1.00 raises the prospect of another deficiency notice and, ultimately, delisting risk, making near-term price stabilization a critical issue. Investors should also monitor upcoming earnings releases and any guidance on whether the company can reverse its revenue decline and narrow its losses.
Additional watch items include progress on remediating the material weaknesses in internal controls, any shifts in customer concentration, the company's cash position relative to its operating needs, and developments in China's regulatory stance toward VIE-structured foreign listings. Because ZCMD is a low-liquidity micro-cap, price action can remain volatile and may not always reflect fundamental news in a linear way.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
It is expected that a price bounce should occur soon.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 50 cases where ZCMD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
Following a +4.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZCMD advanced for three days, in 128 of 173 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
ZCMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZCMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ZCMD entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Seasonality Score of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.464) is normal, around the industry mean (4.523). P/E Ratio (-0.017) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.800) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.002) is also within normal values, averaging (6.105).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. ZCMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZCMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a holding company that engages in the provision of healthcare information, education, and training services
Industry ServicestotheHealthIndustry